Targeted therapy for severe drug reaction (DRESS)
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a targeted therapy for people with a severe drug reaction called DRESS syndrome. It may help control the overactive immune response and reduce organ damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with DRESS syndrome with a score of 4 or more (meaning it's likely or definite)
- You have a fever of at least 100.4°F (38°C) now or in the last 72 hours
- You have at least one affected organ, such as liver, kidneys, lungs, or swollen lymph nodes
- Your blood shows high levels of eosinophils (a type of white blood cell, at least 500 per cubic millimeter)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how certain immune cells (eosinophils) behave during severe drug reactions like DRESS and during milder drug rashes. It may help doctors understand what drives organ damage and improve how these reactions are managed.
This trial compares two medicines—cyclosporine and steroid treatment—for a rare, serious drug reaction called DRESS. It aims to see which treatment controls the illness more safely and effectively.
This study collects skin and blood samples from adults who have a serious rash caused by medicines. The goal is to better understand these reactions and how to diagnose them sooner and more accurately.
This trial tests if a drug called daratumumab can help people with a severe skin reaction (SJS/TEN) caused by a medication. It aims to stop the reaction from getting worse.
This study is for people with severe eosinophilic asthma who are about to start a medicine called Benralizumab (Fasenra). It will observe how the medicine works in real life, and requires you to answer some questions about your asthma every week and month.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
Hear when a new DRESS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.